Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Tarkar A, Schubert B, Yun H, Horton SJ, Agrawal-Singh S, Hähnel PS, Basheer F, Lugo D, Eleftheriadou I, Barbash O, Dhar A, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh PS-H, Dawson MA, Prinjha RK, Huntly BJ and Sasca D (2024). Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation. Blood   

Sánchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jiménez-Pompa A, Gallipoli P and Ganuza M (2024). A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones. Springer Nature  Leukemia  1-13.  

James SC, Atkinson S, Burt R, Lo Celso C and Gallipoli P (2024). Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML. American Society of Hematology  Blood  vol. 144, (Supplement 1) 4152-4152.  

Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Schubert B, Yun H, Horton SJ, Singh SA, Hähnel PS, Basheer F, Lugo D, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh P, Dawson MA, Prinjha R, Huntly BJP and Sasca D (2024). Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation. American Society of Hematology  Blood  vol. 144, (Supplement 1)  

Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif A-L, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R and Belsham E (2024). Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy. American Society of Hematology  Blood Advances  vol. 8, (21) 5590-5597.  

Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P, Kelsall J, Ferguson HR, Patel B, Gallipoli P, Arruda A, Ambinder AJ, Thompson A, Williamson A, Ghiaur G, Minden MD, Gribben JG, Britton DJ, Cutillas PR and Dokal AD (2024). Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia. Elsevier  EBioMedicine  vol. 108,  

Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Avenoso D, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Khorashad J and Apperley JF (2024). Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Springer Nature  Leukemia  vol. 38, (11) 2443-2455.  

Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif A-L, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E and Banerjee S (2024). Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Elsevier  Blood Neoplasia  vol. 1, (3)  

Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J, Wang LM, Campos J, Magee AMS, Woodley K, Austin MJ, Rio-Machin A, Casado P, Bewicke-Copley F, Rodriguez Blanco G, Pereira-Martins D, Oudejans L, Boet E, von Kriegsheim A, Schwaller J, Finch AJ, Patel B, Sarry J-E, Tamburini J, Schuringa JJ, Hazlehurst L, Copland III JA and Yuneva M (2024). Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Springer Nature  Leukemia  vol. 38, (11) 2395-2409.  

Rodriguez Cutillas P, Borek WE, Christopher JA, Nobre LV, Campbell A, Kelsall J, Pedicona F, Nawaz N, Perkins DN, Cardoso PM, Arruda A, Ambinder AJ, Dutta S, Gallipoli P, Sill H, Ghiaur G, Minden MD, Williamson A, Gribben JG and Dokal AD (2024). Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO)  Journal of Clinical Oncology  vol. 42, (16_suppl) 6525-6525.  

Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ, Knight K, Mahdi AJ, Parker J, Virchis A and Apperley JF (2024). Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy. Wiley  British Journal of Haematology  vol. 205, (3) 947-955.  

Lawson H, Holt-Martyn JP, Dembitz V, Kabayama Y, Wang LM, Bellani A, Atwal S, Saffoon N, Durko J, van de Lagemaat LN, De Pace AL, Tumber A, Corner T, Salah E, Arndt C, Brewitz L, Bowen M, Dubusse L, George D, Allen L, Guitart AV, Fung TK, So CWE, Schwaller J, Gallipoli P, O’Carroll D, Schofield CJ and Kranc KR (2024). The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia. Springer Nature  Nature Cancer  vol. 5, (6) 916-937.  

Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif A-L, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S and Potter N (2024). Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. American Society of Hematology  Blood  vol. 143, (4) 336-341.  

Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR and Gallipoli P (2024). Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts. Wiley  HemaSphere  vol. 8, (1)  

Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE, Chen M, Hernandez MCG, Kell WJ, Vachhani P, Agarwal N, Colasante A, Meka S, Smyth A, Ferreira G and Janssen JJWM (2023). Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP). American Society of Hematology  Blood  vol. 142, (Supplement 1)  

Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE, Nawaz N, Ferguson HR, Perkins DN, Moreno‐Cardoso P, Thompson A, Williamson AJK, Minden MD, Gribben JG, Britton DJ and Cutillas PR (2023). S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT‐POSITIVE ACUTE MYELOID LEUKAEMIA. Wiley  HemaSphere  vol. 7, (Suppl)  

Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch A, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman D, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2023). O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS. Elsevier  Leukemia Research  vol. 128,  

Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP and Gallipoli P (2023). Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Springer Nature  Nature Communications  vol. 14, (1)  

Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF and Milojkovic D (2023). The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Springer Nature  Bone Marrow Transplantation  vol. 58, (7) 826-828.  

Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S and Wei AH (2023). C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia. American Association for Cancer Research (AACR)  Cancer Discovery  vol. 13, (7) 1720-1747.  

Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch AJ, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman DH, Bonnet D, Bernard DG, Gribben JG and Rouault-Pierre K (2023). Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia. American Association for the Advancement of Science (AAAS)  Science Translational Medicine  vol. 15, (685) eabn5135-eabn5135.  

Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L, Alunno L, Guitart A, Schwaller J, Gallipoli P, O'Carroll D, Schofield C and Kranc K (2022). Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML. American Society of Hematology  Blood  vol. 140, (Supplement 1) 8731-8732.  

Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Foroni L, Apperley JF and Milojkovic D (2022). Real-World Experience of Asciminib: Factors Associated with Response. American Society of Hematology  Blood  vol. 140, (Supplement 1) 6796-6797.  

Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M, Crolla F, Cross JW, Dang R, Fong CY, Galli S, Gallipoli P, Hogan FL, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Marshall SR, Murthy V, Nagumantry SK, Pillai S, Potter N, Taylor T, Zhao R, Wei AH and Dillon R (2022). Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy. American Society of Hematology  Blood  vol. 140, (Supplement 1) 2033-2035.  

Gallipoli P (2022). AML gets upSET when its dietary needs are unMet. American Society of Hematology  Blood  vol. 140, (19) 2003-2004.  

Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Manteca M-VM, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A and Kremer BE (2022). A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. American Association for Cancer Research (AACR)  Clinical Cancer Research  vol. 29, (4) 711-722.  

Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M, Horne G, Arnold C, Collins A, Cunningham N, Danga A, Frewin R, Garland P, Hannah G, Hassan S, Makkuni S, Rothwell K, Foroni L, Hayden C, Apperley J and Milojkovic D (2022). P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE. Wiley  HemaSphere  vol. 6, 601-602.  

Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM and O’Brien S (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. Wiley  British Journal of Haematology  vol. 196, (6) e55-e57.  

Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A, Bianchi K, Wang J, Gallipoli P, Platzbecker U, Wiseman DH, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2021). Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia. American Society of Hematology  Blood  vol. 138, (Supplement 1)  

Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T, Dang R, Dennis M, Dhawan S, Elliot J, Francis S, Gallipoli P, Hodgson K, Kallmeyer C, Jain M, Katsomitrou V, Khan A, Khwaja A, Kolade S, Krishnamurthy P, Latif A, Laurie J, Lim M, Loke CT, Manson C, Marshall SR, Mobashwera B and Munisamy S (2021). Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service. American Society of Hematology  Blood  vol. 138, (Supplement 1)  

Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J, Campbell VL, Coats T, Collins A, Crawley C, Crolla F, Cross JW, Dalley C, Dang R, Dennis M, Dhawan S, Elliott J, Galli S, Gallipoli P, Hodgson K, Jain M, Kalkur P, Katsomitrou V, Khan A, Khwaja A, Krishnamurthy P, Latif A and Laurie J (2021). Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service. American Society of Hematology  Blood  vol. 138, (Supplement 1)  

Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS and Huntly BJP (2021). Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Springer Nature  Nature Genetics  vol. 53, (10) 1443-1455.  

Dembitz V and Gallipoli P (2021). The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. Frontiers  Frontiers in Oncology  vol. 11,  

Hughes CFM, Gallipoli P and Agarwal R (2021). Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Elsevier  Pathology   

Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P and Deliliers GL (2020). Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Elsevier  Clinical Lymphoma Myeloma & Leukemia  vol. 20, (8) e461-e467.  

Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL and Copland M (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Springer Nature  Leukemia  vol. 34, (7) 1775-1786.  

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P and Huntly BJP (2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. American Society of Hematology  Blood  vol. 134, (24) 2195-2208.  

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D and Apperley JF (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). American Society of Hematology  Blood  vol. 134, (Supplement_1)  

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS and Huntly BJP (2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Rockefeller University Press  Journal of Experimental Medicine  vol. 216, (4) 966-981.  

Gallipoli P and Huntly BJP (2019). Histone modifiers are oxygen sensors. American Association for the Advancement of Science (AAAS)  Science  vol. 363, (6432) 1148-1149.  

Gallipoli P and Huntly BJP (2019). Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML. American Association for Cancer Research (AACR)  Clinical Cancer Research  vol. 25, (2) 460-462.  

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C and Bradley A (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Springer Nature  Nature Communications  vol. 9, (1)  

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2018). Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Springer Nature  Journal of Thrombosis and Thrombolysis  vol. 47, (1) 155-156.  

Gallipoli P (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. Elsevier  Leukemia Research  vol. 75, 71-72.  

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C and Huntly BJP (2018). Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. American Society of Hematology  Blood  vol. 131, (15) 1639-1653.  

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2017). High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Springer Nature  Journal of Thrombosis and Thrombolysis  vol. 45, (1) 106-113.  

Gallipoli P and Huntly BJP (2017). Novel epigenetic therapies in hematological malignancies: Current status and beyond. Elsevier  Seminars in Cancer Biology  vol. 51, 198-210.  

Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL and Michie AM (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood   

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS and Yusa K (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Elsevier  Cell Reports  vol. 17, (4) 1193-1205.  

Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL and Vetrie D (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. American Association for Cancer Research  Cancer Discovery  vol. 6, (11) 1248-1257.  

Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA and Castelli R (2016). Laboratory and clinical risk assessment to treat myelodysplatic syndromes. De Gruyter  Clinical Chemistry and Laboratory Medicine  vol. 54, (9) 1411-1426.  

Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA and Deliliers GL (2015). Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Wolters Kluwer  Anti-Cancer Drugs  vol. 26, (10) 1078-1082.  

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ and Huntly BJP (2015). A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Rockefeller University Press  Journal of Experimental Medicine  vol. 212, (10) 1551-1569.  

Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL and Girolami MA (2015). Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. Systems Genetics  Cambridge University Press (CUP)   

Gallipoli P, Giotopoulos G and Huntly BJP (2015). Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. SAGE Publications  Therapeutic Advances in Hematology  vol. 6, (3) 103-119.  

Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA and Huntly BJP (2015). The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Springer Nature  Oncogene  vol. 35, (3) 279-289.  

Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R and Holyoake TL (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. American Society of Hematology  Blood  vol. 124, (9) 1492-1501.  

Colombo R, Gallipoli P and Castelli R (2014). Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. Elsevier  Clinical Lymphoma Myeloma & Leukemia  vol. 14, (6) 441-450.  

Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P and Pantaleo G (2014). Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Springer Nature  Annals of Hematology  vol. 93, (9) 1523-1529.  

Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P and Huntly B (2013). The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). American Society of Hematology  Blood  vol. 122, (21)  

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL (2013). Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. American Society of Hematology  Blood  vol. 122, (19) 3335-3339.  

Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M and Holyoake TL (2013). Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up. Wiley  British Journal of Haematology  vol. 163, (5) 674-676.  

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X (2013). Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex. Oxford University Press (OUP)  Journal of the National Cancer Institute  vol. 105, (6) 405-423.  

McIlwaine L, Parker A, Sandilands G, Gallipoli P and Leach M (2013). Neutrophil‐specific granule deficiency. Wiley  British Journal of Haematology  vol. 160, (6) 735-735.  

Shah M, Gallipoli P, Lyons J, Holyoake T and Jørgensen H (2012). Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Elsevier  Blood Cells Molecules and Diseases  vol. 48, (3) 199-201.  

Gallipoli P, Abraham SA and Holyoake TL (2011). Hurdles Toward a Cure for CML: The CML Stem Cell. Elsevier  Hematology/Oncology Clinics of North America  vol. 25, (5) 951-966.  

Gallipoli P, Shepherd P, Irvine D, Drummond M and Holyoake T (2011). Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. Wiley  British Journal of Haematology  vol. 155, (1) 128-130.  

DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL and Jiang X (2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. American Society of Hematology  Blood  vol. 116, (21)  

Hamilton A, Gallipoli P, Nicholson E and Holyoake TL (2009). Targeted therapy in haematological malignancies. Wiley  The Journal of Pathology  vol. 220, (4) 404-418.  

Gallipoli P, Clark A and Leach M (2009). The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia. Wiley  American Journal of Hematology  vol. 84, (11) 750-753.  

Fyfe AJ and Gallipoli P (2009). Multiple splenic calcifications. Wiley  British Journal of Haematology  vol. 144, (6) 808-808.  

Gallipoli P, Drummond M and Leach M (2009). Hemophagocytosis and relapsed peripheral T‐cell lymphoma. Wiley  European Journal Of Haematology  vol. 82, (3) 246-246.  

Gallipoli P and Drummond M (2009). Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Wiley  European Journal Of Haematology  vol. 82, (3) 242-243.  

Gallipoli P, Tang A and Leach M (2008). Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. Wiley  British Journal of Haematology  vol. 145, (3) 270-270.  

Gallipoli P and Leach M (2007). Gingival infiltration in acute monoblastic leukaemia. Springer Nature  British Dental Journal  vol. 203, (9) 507-509.  

Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F and Pasanisi F (2005). Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire. Elsevier  Nutrition Metabolism and Cardiovascular Diseases  vol. 16, (3) 168-173.  

Gallipoli P (2002). Medical education: Britain versus Italy. BMJ  The BMJ  vol. 324, (Suppl S2)  

Gallipoli P (2002). Glasgow: a very interesting place. BMJ  The BMJ  vol. 324, (Suppl S2)  

Clark JA, Deutch AY, Gallipoli PZ and Amara SG (1992). Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter. Elsevier  Neuron  vol. 9, (2) 337-348.